Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer-Reference-Cited by-同舟云学术

Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer

Published:2015-04 Issue:2 Volume:24 Page:137-142
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Grant Kathleen A.,Pienaar Fredrieka M.,Brundyn Karen,Swart Gillaume,Gericke George S.,Myburgh Ettienne J.,Wright Colleen A.,Apffelstaedt Justus P.,Kotze Maritha J.

Funder

South African Medical Research Council

National Research Foundation of South Africa

Cape Peninsula University of Technology

Cancer Association of South Africa

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference25 articles.

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

2. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

3. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial;Perez;J Clin Oncol,2006

4. Divisional role of quantitative HER2 testing in breast cancer;Yamamoto-Ibusuki;Breast Cancer,2013

5. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the oncotype DX test: an independent quality assurance study;Dabbs;J Clin Oncol,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating ethical challenges of integrating genomic medicine into clinical practice: Maximising beneficence in precision oncology;South African Journal of Bioethics and Law;2024-04-23

2. Comparative Study on Clinicopathological Characteristics of Breast Cancer in Vietnam and Italy;Clinical and Experimental Obstetrics & Gynecology;2022-09-01

3. Reclassification of early stage breast cancer into treatment groups by combining the use of immunohistochemistry and microarray analysis;South African Journal of Science;2019-03-27

4. Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint;Journal of Global Oncology;2017-08

5. Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases;Journal of Translational Medicine;2017-05-01